(19)
(11) EP 2 853 543 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
13.05.2015 Bulletin 2015/20

(88) Date of publication A3:
01.04.2015 Bulletin 2015/14

(43) Date of publication:
01.04.2015 Bulletin 2015/14

(21) Application number: 13794561.4

(22) Date of filing: 22.05.2013
(51) International Patent Classification (IPC): 
C07K 16/24(2006.01)
C12N 15/63(2006.01)
A61P 37/06(2006.01)
 C12N 15/13(2006.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/CN2013/076074
(87) International publication number:
WO 2013/174264 (28.11.2013 Gazette 2013/48)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 22.05.2012 CN 201210160474

(71) Applicants:
  • Wuhan Therasource Biosciences Inc
    Wuhan Hubei 430075 (CN)
  • Shanghai Union Biopharm Co., Ltd.
    Pudong Shanghai 201023 (CN)

(72) Inventors:
  • CHEN, Bo
    Wuhan Hubei 430075 (CN)
  • FENG, Hui
    Wuhan Hubei 430075 (CN)
  • SHU, Hongbing
    Wuhan Hubei 430075 (CN)

(74) Representative: Meissner, Bolte & Partner GbR 
Widenmayerstrasse 47
80538 München
80538 München (DE)

   


(54) ANTI-BLYS ANTIBODY


(57) The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and/or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematorsus.